Lisa Kaltenbrunner

• Represented Bain Capital Life Sciences as it led an over $200 million strategic growth transaction centered on Serán Bioscience, a leading contract development and manufacturing organization (CDMO) providing development, analytical and manufacturing services to pharmaceutical and biotechnology companies.
• Represented AvenCell Therapeutics in its $112 million Series B funding round led by global life sciences investor Novo Holdings.
• Advised Basecamp Research, a London-based startup and market leader in mapping biodiversity for AI-based design of biological systems, on its $60 million Series B funding round.
• Represented Bluecat Networks in its acquisition of LiveAction, a global provider of network observability and intelligence solutions.
• Represented TSG Consumer Partners in its acquisition of Legacy.com, a provider of online funeral information and obituary services.
• Advised EQT Private Capital Asia on its acquisition of PropertyGuru Group Limited for $1.1 billion.
• Advised Allorion Therapeutics in a global licensing agreement with Avenzo Therapeutics to develop and commercialize Allorian's AVZO-021, a cyclin-dependent kinase 2 selective inhibitor globally, excluding Greater China.
• Represented Japanese drugmaker Sumitomo Pharma and its U.S. subsidiary Sumitomo Pharma America (SMPA) in a revised license agreement with Otsuka Pharmaceuticals.
• Advised H.I.G. Infrastructure, the infrastructure arm of H.I.G. Capital, in the acquisition of Tower Engineering Professionals, Inc. (TEP), a leading full-service provider of engineering and maintenance services to tower, mobile network, and other telecom infrastructure customers.
• Represented Berkshire Partners in its strategic investment alongside Leonard Green & Partners in Vital Care, an infusion services company.
• Represented SkyKnight Capital and Dragoneer Investment Group in the joint acquisition of a majority stake in Simplicity, a financial products distribution firm, from Lee Equity Partners.
• Represented San Francisco-based Vir Biotechnology in an exclusive worldwide license agreement with Sanofi for three clinical stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases acquired by Sanofi from Amunix Pharmaceuticals.
• Represented the L.S. Starrett Company (Starrett) in its agreement to be sold to MiddleGround Capital for $16.19 per share.
• Represented Avista Capital Partners in its sale of a significant equity interest in Cosette Pharmaceuticals, a U.S.-based specialty pharmaceutical company, to funds managed by Hamilton Lane.
• Advised TSG Consumer Partners in its investment in Summer Fridays, a clean, premium skincare and hybrid makeup brand. 
• Advising Nippon Steel Corporation on its ~$14 billion bid for US Steel.
• Advised Audax Private Equity in an investment in BlueCat Networks, a provider of network infrastructure.
• Advised the Sports Entertainment Acquisition Corporation (SEAH), a publicly traded special purpose acquisition company, in its merger with SGHC Limited, the parent company of Betway, a leading online sports betting and gaming business.
• Advised Galderma, one of the world’s largest independent dermatology companies, in its acquisition of Alastin Skincare, Inc.
• Advised global medical technology leader Medtronic plc. in an agreement to acquire all outstanding shares of Intersect ENT in an all cash transaction for an approximate value of $1.1 billion.
• Advised E-mart Inc. in its approximately $3 billion acquisition of 80.01% interest in eBay’s businesses in South Korea.
• Advised 3i Group plc on its investment in Digital Barriers, a leading provider of IoVT (Internet of Video Things) surveillance and security products.
• Advised Pfizer Inc. in its acquisition of Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, for approximately $2.26 billion.
• Advised Pulsant, one of the leading nationwide providers of data centre and cloud infrastructure in the UK, on its sale from Oak Hill Capital and Scottish Equity Partners to Antin Infrastructure Partners.
• Advised Blackstone Life Sciences in its combination with gene editing drugmaker Intellia Therapeutics, Inc. and German cell manufacturer Cellex Cell Professionals GmbH to create a new CAR T-cell company to develop cell therapies for cancer and autoimmune diseases.
• Advised Inflexion, a UK-headquartered private equity firm, and other shareholders (including the management team) on the sale of Reed & Mackay, a premium corporate travel management and events business, to TripActions, a U.S.-headquartered business travel and spend management platform.
• Advised NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, on its acquisition – including its financing via private placement of equity – of Inivata Ltd, a global, commercial stage liquid biopsy platform company, headquartered in Cambridge, UK.
• Advised Asklepios BioPharmaceutical, a U.S. biopharmaceutical company specialised in the development of gene therapies, on its sale to Bayer AG.
• Advising Wright Medical Group N.V. on its agreement to be acquired by Stryker Corp. in a transaction with a total enterprise value of approximately $5.4 billion.

Notable transactions in which Lisa has been involved prior to joining the firm include:

• Advised a global investment bank on multiple European Commission Article 101 investigations, including the Commission’s investigation into Credit Default Swaps, LIBOR and EURIBOR interest rate derivatives.
• Successfully defended a whistle-blower in its immunity application in front of the European Commission and national competition authorities.
• Acted for a global payment service provider in the European Commission’s antitrust investigation in relation to Multilateral Interchange Fees.
• Advised a pharmaceutical company on its appeal against the Competition and Market’s excessive pricing decision.
• Acted for a pharmaceutical company on its appeal to the Competition Appeal Tribunal in relation to the Competition and Markets Authority’s pay-for-delay decision.
• Advised a global network and telecoms supplier on its pricing compliance with Article 102 and distribution contracts.
• Advised a leading European payment card operator in its engagement with the UK Payment Service Regulator.
• Advised a UK Fintech on competition law compliance during its launch to market.
• Acted for two collecting societies on the successful establishment of a market-facing joint venture.
• Advised a global corporate client on European merger control aspects in relation to its strategic investment.
• Advised a TV advertisement client in relation to a UK merger filing.
• Advised a large UK real estate contractor on potential sale of stake to foreign investor.